Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.

Kim N. Chi,Fred Saad,Simon Chowdhury,Julie N. Graff,Neeraj Agarwal,Stéphane Oudard,Gang Li,Angela Lopez-Gitlitz,Julie S. Larsen,Sharon Anne McCarthy,Suneel Mundle,Matthew R. Smith,Eric J. Small

Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.

2020

Kim N. Chi
Fred Saad
Simon Chowdhury
Julie N. Graff
Neeraj Agarwal
Stéphane Oudard
Gang Li
Angela Lopez-Gitlitz
Julie S. Larsen
Sharon Anne McCarthy
Suneel Mundle
Matthew R. Smith
Eric J. Small

5541Background: The phase III TITAN and SPARTAN studies demonstrated improved outcomes with the addition of apalutamide (APA) to androgen deprivation therapy (ADT); outcomes included prolonging ove...

Keywords:

Internal medicine
Oncology
Apalutamide
Prostate-specific antigen
psa kinetics
Pathology
Prostate cancer
in patient
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations